Targeted chondroitinase ABC fusion proteins and complexes thereof
Described herein are targeted ChABC fusion proteins, complexes thereof, and uses thereof. The targeted ChABC fusion proteins can include a ChABC polypeptide that can be linked to a Gal-3 polypeptide. Monomer targeted ChABC fusion proteins can form homogeneous or heterogeneous complexes. The targeted ChABC fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted ChABC fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.
1 . A targeted effector fusion protein comprising a polypeptide sequence that is identical to any one of SEQ ID NOs: 15-16.
2 . A multimeric targeted effector fusion protein complex comprising:
at least two targeted effector fusion proteins, wherein each of the at least two targeted effector proteins is according to claim 1 , and the at least two targeted effector proteins are conjugated to each other by binding between an alpha coil polypeptide or a random coil polypeptide in each of the at least two targeted effector proteins.
3 . The multimeric targeted effector fusion protein complex of claim 2 , wherein the multimeric targeted effector fusion protein complex is homogeneous.
4 . The multimeric targeted effector fusion protein complex of claim 2 , wherein the multimeric targeted effector fusion protein complex is heterogeneous.
5 . A polynucleotide that encodes the targeted effector fusion protein of claim 1 .
6 . The polynucleotide of claim 5 , wherein the polynucleotide sequence is SEQ ID NO: 6 or 7.
7 . A vector comprising:
a polynucleotide according to claim 5 .
8 . A single fusion polypeptide sequence comprising:
at least two targeted effector fusion proteins as in claim 1 , wherein each of the at least two targeted effector fusion proteins are directly fused at the C-terminus, N-terminus, or both the C-terminus and N-terminus of at least one other targeted effector fusion protein of the at least two targeted effector fusion proteins.
9 . A single fusion polypeptide sequence comprising:
at least two targeted effector fusion proteins as in claim 1 , wherein each of the at least two targeted effector fusion proteins are operatively linked at the C-terminus, N-terminus, or both the C-terminus and N-terminus to at least one other targeted effector fusion protein of the at least two targeted effector fusion proteins via one or more additional amino acids.
10 . A polynucleotide encoding the single fusion polypeptide of claim 8 .
11 . A vector comprising:
the polynucleotide according to claim 10 .
12 . A pharmaceutical formulation comprising:
one or more targeted effector fusion proteins as in claim 1 ; and
a pharmaceutically acceptable carrier.